• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

ICYMI: Top Highlights From AMCP Nexus 2022


The Academy of Managed Care Pharmacy (AMCP) Nexus 2022, the annual fall meeting of AMCP, took place October 11-14, 2022, in National Harbor, Maryland. The meeting featured a keynote from one of the top physician-executives in health care, the specialty pharmaceutical pipeline, and insights for managed care stakeholders in selecting and integrating cost-effective, value-based care frameworks.

Here are some of the highlights of AMCP Nexus 2022.

Inflation Reduction Act, Health Equity at Forefront of Federal Policy Action Amid Midterm Elections, Panel Says

Recent federal legislative and regulatory updates in managed care pharmacy have prioritized topics ranging from expedited access to novel therapeutics to the health disparities and equity concerns affecting patient populations nationwide, but progress on these developments will depend on the impact of the upcoming midterm elections, according to stakeholders of a panel discussion.

Growing Innovation, Cost Expected in the Oncology Drug Pipeline

Oncology represents more than a third of specialty drugs in the pipeline with substantial growth seen in recent years for clinical development and accelerated approvals. But rising cost of these new and emerging therapeutics continues to have major implications for managed care stakeholders, according to experts of the concluding keynote session.

Examining Cost-effectiveness, Efficacy of Combination Therapies in HIV

Two posters addressed the cost-effectiveness of guideline-recommended integrase strand transfer inhibitor–based triple therapy in people living with HIV, as well as the efficacy of adjuvant lenacapavir in treatment-naïve patients.

Payers Need Enhanced Utilization Management to Optimize High-Cost Therapies, Panel Says

Panelists discussed enhanced utilization management strategies to manage the rising cost of specialty drugs, while providing members with support for rare, complex conditions.

Related Videos
Dr Jessica Robinson-Papp
Dr. Jessica Robinson-Papp
Dr. Robinson-Papp
Related Content
© 2023 MJH Life Sciences
All rights reserved.